收费全文 | 334384篇 |
免费 | 19822篇 |
国内免费 | 490篇 |
耳鼻咽喉 | 4596篇 |
儿科学 | 11408篇 |
妇产科学 | 11056篇 |
基础医学 | 50980篇 |
口腔科学 | 7854篇 |
临床医学 | 27725篇 |
内科学 | 65007篇 |
皮肤病学 | 7150篇 |
神经病学 | 24620篇 |
特种医学 | 12746篇 |
外国民族医学 | 74篇 |
外科学 | 51370篇 |
综合类 | 7873篇 |
现状与发展 | 1篇 |
一般理论 | 166篇 |
预防医学 | 22691篇 |
眼科学 | 7556篇 |
药学 | 23481篇 |
中国医学 | 859篇 |
肿瘤学 | 17483篇 |
2021年 | 2807篇 |
2019年 | 2885篇 |
2018年 | 4681篇 |
2017年 | 3417篇 |
2016年 | 3804篇 |
2015年 | 4394篇 |
2014年 | 5572篇 |
2013年 | 8754篇 |
2012年 | 11664篇 |
2011年 | 12011篇 |
2010年 | 7428篇 |
2009年 | 6617篇 |
2008年 | 11007篇 |
2007年 | 11903篇 |
2006年 | 11581篇 |
2005年 | 11285篇 |
2004年 | 10922篇 |
2003年 | 10237篇 |
2002年 | 9784篇 |
2001年 | 14316篇 |
2000年 | 14715篇 |
1999年 | 12288篇 |
1998年 | 3259篇 |
1997年 | 2971篇 |
1996年 | 2811篇 |
1995年 | 2703篇 |
1994年 | 2486篇 |
1992年 | 8826篇 |
1991年 | 8909篇 |
1990年 | 8722篇 |
1989年 | 8500篇 |
1988年 | 7699篇 |
1987年 | 7455篇 |
1986年 | 7067篇 |
1985年 | 6837篇 |
1984年 | 4997篇 |
1983年 | 4309篇 |
1982年 | 2585篇 |
1979年 | 4585篇 |
1978年 | 3331篇 |
1977年 | 2833篇 |
1976年 | 2598篇 |
1975年 | 2920篇 |
1974年 | 3476篇 |
1973年 | 3468篇 |
1972年 | 3226篇 |
1971年 | 3072篇 |
1970年 | 2947篇 |
1969年 | 2714篇 |
1968年 | 2646篇 |
Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献
Area covered: The authors discuss, herein, the need for developing radiation countermeasure agents for various sub-syndromes of acute radiation syndromes (ARS) following TBDD and PBDD approaches. With time and continuous advances in radiation countermeasure drug development research, the expectation is to have multiple radiation countermeasure agents for each sub-syndrome made available to radiation exposed victims.
Expert opinion: The majority of the countermeasures currently being developed for ARS employ the PBDD approach, while the TBDD approach is clearly under-utilized. In the future, an improved drug development strategy might be a ‘hybrid’ strategy that is more reliant on TBDD for the initial drug discovery via large-scale screening of potential candidate agents, while utilizing PBDD for secondary screening of those candidates, followed by tertiary analytics phase in order to pinpoint efficacious candidates that target the specific sub-syndromes of ARS. 相似文献